STAR SPORTS MED

1609
52.5000.00% ( 0.000 )
Delay Closed: Nov 16, 16:08:11

Overview

STAR SPORTS MED (1609)

Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such a...

Open
55.050
High
55.050
Low
49.180
Prev. Close
52.500
Volume
120.10K
Turnover
6.13M
Avg Price
51.014
Bid/Ask Ratio
-94.59%
Amplitude
11.18%
52wk High
299.000
Volume Ratio
2.68
Turnover Ratio
0.22%
52wk Low
47.260
HK Mkt Cap
2.87B
Market CapHKD
2.87B
P/ETTM
19.56
P/EDynamic
45.43
P/EStatic
--
EPSTTM
2.68
EPSDynamic
1.16
EPSStatic
--
BVPS
27.46
P/B
1.91
HK Shares
54.60M
Dividend YieldTTM
--
DividendTTM
--
Shares
54.60M
Min lot size
50
Currency
HKD

Daily Events

  1. Nov, 16

    Star Sports Medicine (1609.HK) reversed early gains to close down 6.1% at HK$49.30, having touched HK$54.05 at 9:31 BJ before a steady afternoon slide to the session low, as the IPO cornerstone investors' lock-up approached expiry; volume was thin at 117,050 shares worth HK$5.96 million, a 0.21% turnover rate. The stock had already fallen 22.69% over the prior week and printed a 52-week low of HK$47.26 on 3 November, leaving it more than 80% below its HK$299 peak on 4 May and down over 70% year-to-date. It now sits below its 20-day average of HK$52.87 and about 45% below its 60-day average of HK$89.50. The company has filed several next-day disclosure returns on share buybacks and shareholders approved a 2026 incentive scheme at an extraordinary meeting, while the HK$2.89 billion market value carries a 19.73x PE and 1.93x PB; though buybacks at such low turnover have so far absorbed little of the selling.

  2. Nov, 13

    Shares fell 4.63% to HK$52.55 as the approaching expiry of IPO cornerstone lock-ups weighed on sentiment, with the stock spiking to HK$56.00 in the morning session before sliding to a HK$52.05 low at 14:51 BJ and settling near the day's trough on 63,050 shares worth HK$3.36m, a thin 0.12% turnover. The move extends a 22.69% weekly decline and follows a HK$47.26 52-week low on 3 November; at HK$52.55 the price sits 82.42% below the HK$299 peak of 4 May and down 75.56% year-to-date, beneath both MA20 (HK$53.70) and MA60 (HK$91.06). The company has repeatedly disclosed share buybacks in HKEX next-day returns and shareholders approved the 2026 incentive scheme, with market capitalisation of about HK$2.87bn, PE 19.58x and PB 1.91x. Though the buyback scale remains small relative to market value.

  3. Nov, 10

    After sliding to a 52-week low of HK$47.26 on 3 November, Star Sports Medicine opened at HK$51.05, its session low, pushed to HK$53.75 at 13:29, faded to HK$51.80 late and settled at HK$52.55, up about 3.0%, on just 86,850 shares and HK$4.56 million turnover (0.15% turnover rate), a spike-then-fade pattern. The move followed a week in which roughly 2.92 million cornerstone shares reach lock-up expiry this Thursday, alongside single-day declines of 7%-9% in late October; the company has bought back stock repeatedly since 27 October, including 10,000 shares for HK$483,900 on 3 November, absorbing part of the supply. The price remains below its MA20 of HK$55.57 and MA60 of HK$96.01, down 75.56% year to date and 82.42% below the HK$299 high of 4 May, at 19.59x PE. Though thin volume leaves the support untested.

  4. Nov, 9

    Star Sports Medicine reversed early gains, gapping up to HK$55.40 at the open before fading to close at HK$51.45, down 2.0% from the previous HK$52.50, with the afternoon session touching HK$50.10 on only 115,350 shares worth about HK$5.94 million, a 0.21% turnover rate. The overhang is concentrated on 2.92 million cornerstone shares whose lock-up expires Thursday; the stock set a 52-week low of HK$47.26 on November 3, sits 82.8% below its 52-week high and is down 76.1% year to date, still under its MA20 of HK$56.14. Buybacks have run since October 27, including 10,000 shares for HK$483,900 on November 3, offering limited support. At 19.18x PE and HK$2.81 billion market cap, though, whether repurchases can absorb the unlock supply remains open.

  5. Nov, 6

    With the IPO cornerstone investors' lock-up expiring this Thursday and roughly 2.92 million shares due to become tradable, the stock closed at HK$52.70, down 3.9% from the prior close of HK$54.85, tracing a gap-up-then-fade pattern: it opened at HK$55.85, printed HK$55.60 at 09:30 and slid to HK$50.70 in the morning session, on only 98,500 shares and HK$5.21 million turnover, a 0.16% turnover rate. Buybacks since late October, including 17,000 shares for HK$921,000 on Oct 28 and another 10,000 shares for about HK$483,900 on Nov 3, have not reversed the slide. The shares are down 75.3% year to date and 82.3% below the HK$299 52-week high of May 4, sitting just 12.3% above the HK$47.26 low touched on Nov 3 and below both the MA20 of HK$56.77 and MA60 of HK$99.01. Still, it stood as the largest domestic sports-medicine implant supplier in 2024 with a 6.5% share, at a PE of 19.8x.

News